Lipoprotein-associated phospholipase A2 (Lp-PLA2): Difference between revisions
Jump to navigation
Jump to search
Brian Blank (talk | contribs) No edit summary |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
(One intermediate revision by the same user not shown) | |||
Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Line 12: | Line 12: | ||
--> | --> | ||
[[Category:Cardiology]] | [[Category:Cardiology]] | ||
[[Category:Biomarker]] | [[Category:Biomarker]] |
Latest revision as of 19:06, 4 September 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme that can modify low-density lipoproteins and may be involved in atherogenesis and the risk of coronary artery disease. In a nested case-control study, patients in the highest quintile of Lp-PLA2 levels had nearly twice the odds of coronary events compared with patients in the lowest quintile.